Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4+ CD25+ regulatory t cells

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Ataera, Haley ^a,b   Hyde, Evelyn ^a   Price, Kylie M ^a   Stoitzner, Patrizia ^a,c   Ronchese, Franca ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; RAG 1 PROTEIN; RAG-1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA B16; MOUSE; NONHUMAN; PHENOTYPE; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR GROWTH; TUMOR INFILTRATING DENDRITIC CELL; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MELANOMA; METABOLISM; PATHOLOGY;

MURINAE; MUS;

ANIMALS; ANTIGEN PRESENTATION; CELL PROLIFERATION; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEINS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPH NODES; LYMPHOCYTE DEPLETION; MELANOMA; MICE; MICE, INBRED C57BL; PHENOTYPE; T-LYMPHOCYTES, REGULATORY;

EID: 79952293782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017515     Document Type: Article

References (55)

1. Vicari AP, Caux C, Trinchieri G, (2002) Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 12: 33-42.
2. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, et al. (1999) Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 190: 125-133.
3. Stoitzner P, Green LK, Jung JY, Price KM, Ataera H, et al. (2008) Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother 57: 1665-1673.
4. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, et al. (2003) Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 104: 92-97.
5. Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, et al. (2005) Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 11: 2576-2582.
6. Chaux P, Favre N, Martin M, Martin F, (1997) Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 72: 619-624.
7. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, et al. (2002) Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 196: 541-549.
8. Pinzon-Charry A, Maxwell T, Lopez JA, (2005) Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83: 451-461.
9. Preynat-Seauve O, Schuler P, Contassot E, Beermann F, Huard B, et al. (2006) Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol 176: 61-67.
10. Gerner MY, Casey KA, Mescher MF, (2008) Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol 181: 155-164.
11. + Treg. Eur J Immunol 39: 1323-1333.
12. + T cell function via L-arginine metabolism. Cancer Res 69: 3086-3094.
13. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, et al. (2010) Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 16: 880-886.
14. Engleman EG, Brody J, Soares L, (2004) Using signaling pathways to overcome immune tolerance to tumors. Sci STKE 2004: pe28.
15. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S, (2003) Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 24: 335-342.
16. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD, (2006) Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 66: 7301-7309.
17. + regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121: 95-105.
18. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, et al. (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A 102: 419-424.
19. Shevach EM, (2006) From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25: 195-201.
20. Billiard F, Litvinova E, Saadoun D, Djelti F, Klatzmann D, et al. (2006) Regulatory and effector T cell activation levels are prime determinants of in vivo immune regulation. J Immunol 177: 2167-2174.
21. + T regulatory cell-mediated suppression. Immunity 30: 636-645.
22. Asano M, Toda M, Sakaguchi N, Sakaguchi S, (1996) Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184: 387-396.
23. Kim JM, Rasmussen JP, Rudensky AY, (2007) Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 8: 191-197.
24. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, et al. (2004) Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21: 589-601.
25. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, et al. (2004) Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104: 2840-2848.
26. + regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling. J Immunol 179: 3578-3587.
27. + regulatory T cells inhibits the induction of inflammatory mediators. J Immunol 180: 2747-2751.
28. + regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 66: 10145-10152.
29. + regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30: 1538-1543.
30. + T cells. Immunity 19: 877-889.
31. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, et al. (2006) Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 7: 83-92.
32. + T cells and dendritic cells in vivo. J Exp Med 203: 505-511.
33. Darrasse-Jeze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, et al. (2009) Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 206: 1853-1862.
34. Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, et al. (2009) In vivo analysis of dendritic cell development and homeostasis. Science 324: 392-397.
35. + T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 32: 266-278.
36. Thompson ED, Enriquez HL, Fu YX, Engelhard VH, (2010) Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 207: 1791-1804.
37. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, et al. (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22: 329-341.
38. + regulatory T cells. J Immunol 174: 90-98.
39. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, et al. (2005) Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174: 7516-7523.
40. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
41. Carbone FR, Belz GT, Heath WR, (2004) Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol 25: 655-658.
42. Kieper WC, Jameson SC, (1999) Homeostatic expansion and phenotypic conversion of naive T cells in response to self peptide/MHC ligands. Proc Natl Acad Sci U S A 96: 13306-13311.
43. + regulatory T cells in tumor bearing host. Cell Mol Immunol 6: 3-13.
44. Beyer M, Schultze JL, (2006) Regulatory T cells in cancer. Blood 108: 804-811.
45. + DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur J Immunol 40: 1617-1627.
46. Shreedhar V, Moodycliffe AM, Ullrich SE, Bucana C, Kripke ML, et al. (1999) Dendritic cells require T cells for functional maturation in vivo. Immunity 11: 625-636.
47. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, et al. (1999) Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 189: 331-339.
48. Scheinecker C, McHugh R, Shevach EM, Germain RN, (2002) Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 196: 1079-1090.
49. Gerner MY, Mescher MF, (2009) Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol 182: 2726-2737.
50. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, et al. (2004) Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 173: 5923-5928.
51. + CTL to cause tumor eradication. J Immunol 173: 6753-6759.
52. McLachlan JB, Catron DM, Moon JJ, Jenkins MK, (2009) Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity 30: 277-288.
53. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218.
54. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI, (2008) Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 333: 167-179.
55. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, et al. (2006) Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25: 129-141.